trending Market Intelligence /marketintelligence/en/news-insights/trending/m65sxoxame03mdbbqr5rnq2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Agios CEO to step down; will be replaced by former Celgene president/COO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Agios CEO to step down; will be replaced by former Celgene president/COO

Agios Pharmaceuticals Inc. said David Schenkein will step down as CEO on Feb. 1, 2019 and become executive chairman of the board.

Schenkein has served as CEO of the Cambridge, Mass.-based company since 2009 and oversaw the U.S. approval of two cancer medicines.

Jacqualyn Fouse, who joined Agios' board in December 2017, will succeed Schenkein as CEO. She will remain on the board of directors.

Fouse previously worked as president and COO of Summit, N.J.-based biopharmaceutical company Celgene Corp.

Further, Agios Chairman John Maraganore will become a director when Schenkein becomes chairman.